Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team J Dyson, B Jaques, D Chattopadyhay, R Lochan, J Graham, D Das, ... Journal of hepatology 60 (1), 110-117, 2014 | 673 | 2014 |
Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging JK Dyson, QM Anstee, S McPherson Frontline gastroenterology 5 (3), 211-218, 2014 | 453 | 2014 |
Primary sclerosing cholangitis JK Dyson, U Beuers, DEJ Jones, AW Lohse, M Hudson The Lancet 391 (10139), 2547-2559, 2018 | 416 | 2018 |
The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines GM Hirschfield, JK Dyson, GJM Alexander, MH Chapman, J Collier, ... Gut 67 (9), 1568-1594, 2018 | 352 | 2018 |
Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? JK Dyson, MD Rutter World journal of gastroenterology: WJG 18 (29), 3839, 2012 | 298 | 2012 |
British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis MH Chapman, D Thorburn, GM Hirschfield, GGJ Webster, SM Rushbrook, ... Gut 68 (8), 1356-1378, 2019 | 253 | 2019 |
Republished: non-alcoholic fatty liver disease: a practical approach to treatment JK Dyson, QM Anstee, S McPherson Postgraduate medical journal 91 (1072), 92-101, 2015 | 198 | 2015 |
Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK R Williams, G Alexander, I Armstrong, A Baker, N Bhala, G Camps-Walsh, ... The Lancet 391 (10125), 1097-1107, 2018 | 181 | 2018 |
Novel therapeutic targets in primary biliary cirrhosis JK Dyson, GM Hirschfield, DH Adams, U Beuers, DA Mann, KD Lindor, ... Nature reviews Gastroenterology & hepatology 12 (3), 147-158, 2015 | 143 | 2015 |
The new epidemiology of primary biliary cirrhosis L Griffiths, JK Dyson, DEJ Jones Seminars in liver disease 34 (03), 318-328, 2014 | 119 | 2014 |
Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use JK Dyson, J Hutchinson, L Harrison, O Rotimi, D Tiniakos, GR Foster, ... Journal of hepatology 64 (1), 234-238, 2016 | 110 | 2016 |
Implementation of the lancet standing commission on liver disease in the UK R Williams, K Ashton, R Aspinall, MA Bellis, J Bosanquet, ME Cramp, ... The Lancet 386 (10008), 2098-2111, 2015 | 107 | 2015 |
Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification JK Dyson, S McPherson, QM Anstee Journal of clinical pathology 66 (12), 1033-1045, 2013 | 88 | 2013 |
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group S Pape, RJ Snijders, TJG Gevers, O Chazouilleres, GN Dalekos, ... Journal of hepatology 76 (4), 841-849, 2022 | 86 | 2022 |
The inter‐relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis JK Dyson, N Wilkinson, L Jopson, G Mells, A Bathgate, MA Heneghan, ... Alimentary pharmacology & therapeutics 44 (10), 1039-1050, 2016 | 85 | 2016 |
Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score VS Hegade, A Khanna, LJ Walker, LL Wong, JK Dyson, DEJ Jones Digestive diseases and sciences 61, 3037-3044, 2016 | 83 | 2016 |
Unmet clinical need in autoimmune liver diseases JK Dyson, G Webb, GM Hirschfield, A Lohse, U Beuers, K Lindor, ... Journal of hepatology 62 (1), 208-218, 2015 | 81 | 2015 |
Treatment of non-alcoholic fatty liver disease J Dyson, C Day Digestive diseases 32 (5), 597-604, 2014 | 75 | 2014 |
Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK R Williams, G Alexander, R Aspinall, R Batterham, N Bhala, N Bosanquet, ... The Lancet 392 (10162), 2398-2412, 2018 | 73 | 2018 |
The impact of autoimmune hepatitis and its treatment on health utility LL Wong, HF Fisher, DD Stocken, S Rice, A Khanna, MA Heneghan, ... Hepatology 68 (4), 1487-1497, 2018 | 67 | 2018 |